Nalaganje...
Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies
Pembrolizumab is an immune checkpoint inhibitor (programmed cell death 1) approved for use in non-small cell lung carcinoma (NSCLC). Pembrolizumab has shown remarkable results in regression of the size of tumors in NSCLC and has shown survival advantage. However, immune-related adverse effects are a...
Shranjeno v:
| izdano v: | Cureus |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Cureus
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7386084/ https://ncbi.nlm.nih.gov/pubmed/32754380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.8836 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|